Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Multimillion Pound Investment in UK Life Sciences Research and Development

Published: Wednesday, December 11, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
UCB invests over £3 million in new bespoke cutting-edge robotic platform for UK R&D HQ.

UCB has today announced the successful completion of a £3.29 million investment in new, cutting-edge robotic laboratory equipment and purpose-built technology at its UK immunology research centre of excellence. The investment centres on an automated antibody discovery platform, designed and built especially for UCB by Farnborough based robotic laboratory experts company Peak Analysis & Automation Ltd (PAA).

Today, medicine discovery is a sophisticated process that integrates scientific innovation with cutting-edge technology and the new equipment enhances our search for new medicines by providing UCB with a highly automated process to effectively generate, select, produce and evaluate new human antibody-based medicines for patients. Coupling our scientists’ know-how and innovation with smart automation should shorten development life cycles and improve clinical success rates.

Today’s announcement from UCB coincides with the Prime Minister’s speech welcoming progress made in the two years since the Government’s Life Sciences Strategy was launched. The strategy acknowledged the valuable contribution the pharmaceutical industry makes to the UK and signalled the Government’s commitment to growing this sector. Without the subsequent reforms to the R&D tax credit system, announced in last year’s autumn statement, this new inward investment to the UK by UCB may not have happened.

“UCB’s decision to commission their new robotic laboratory equipment from the local Farnborough-based company PAA is a wonderful example of a UK leader in science choosing to partner with a local UK specialist company to strengthen this country’s world class science offering”, explained Sir Gerald Howarth, Member of Parliament for Aldershot. He added, “The fact that UCB had the confidence to invest in the future of their UK drug discovery research facilities provides evidence that the Government’s Life Sciences strategy is delivering on the ground results.”

With many pharmaceutical companies downsizing their UK R&D facilities and relocating to cheaper overseas locations combined with more company restructuring on the horizon, it is clearly a difficult environment for the pharmaceutical industry. However UCB’s announcement underlines the company’s ongoing commitment to pioneering scientific innovation in the UK and reinforces its position as a science skills leader.

Speaking on behalf of UCB, Dr Neil Weir, Senior Vice President of Discovery, UCB and Chair of the ABPI Innovation Board said “Some 40% of UCB’s total global research spend takes place in the UK. We choose to invest in this country because of the calibre of UK scientists, as well as the Government’s commitment to life sciences funding. This pioneering new robotic technology marks a significant step forward in our ability to develop exciting novel and effective treatments, making UCB’s UK research capabilities more competitive in the global race for drug development. He added, “Previously, UCB were effectively penalised because our R&D spend outweighed our sales to the NHS, making us ineligible for the R&D tax credit. The Government’s reforms to the tax credit will release several million pounds for UCB, which has given us the confidence to make this investment”.

Describing UCB’s decision to partner with PAA, Mike Collins, PAA’s Finance Director, explained, “Wherever possible PAA manufacture all elements of our commissions locally. We place a high value on this philosophy because of the improved control it gives us over quality and deliveries. UCB’s decision to appoint PAA for this project validates this approach and is a great example of a leading UK science organisation partnering with a leading UK robotics supplier – helping to ensure our team of computer scientists, robotic specialists, analytical chemists, physicists and electronic engineers remain in the UK”.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB Announces US and EU Regulatory Filings for Brivaracetam
Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures.
Tuesday, January 27, 2015
Scientists Invited to Access New Cutting-edge Technology Platform
UCB announces that it has launched its ‘Technology Platform Access’, a collaboration programme for the discovery and development of novel antibodies against potential therapeutic targets.
Thursday, May 01, 2014
UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
Strategic collaboration commences with three discovery programs in areas of high patient need.
Friday, April 04, 2014
UCB CEO to Chair IMI Board for a Second Term
Roch Doliveux to spearhead industry’s commitment to world’s biggest public-private partnership in biopharmaceutical research and innovation.
Wednesday, April 02, 2014
UCB and Sanofi Partner for Innovation in Immune-Mediated Diseases
Goal is to identify novel small molecule therapies to address a wide range of immune-mediated diseases.
Friday, March 14, 2014
UCB and Biogen Idec Enter Agreement
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s innovative therapies to patients in new markets.
Friday, January 31, 2014
Online Challenge to Find Next Generation of Breakthrough Medicines
UCB announces the global launch of its ‘Innovation Challenge’ which seeks to find rare phenotypes.
Tuesday, January 28, 2014
UCB Receives CHMP Positive Opinion for Cimzia in Active PsA
Positive opinion is supported by data from the RAPID™-PsA study.
Monday, October 28, 2013
Vectura and UCB to Collaborate and Share Expertise in Severe Inflammatory
Collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory.
Tuesday, October 01, 2013
UCB Announces Third Research Collaboration with Harvard University
New Research Alliance project to focus on human microbiome to develop new therapeutic applications in immunology.
Wednesday, October 10, 2012
UCB Announces Start of C-EARLY™ Study for Cimzia® in RA
Phase III study to evaluate Cimzia® (certolizumab pegol) in adult patients with early, active, moderate to severe rheumatoid arthritis who have not been exposed to disease-modifying antirheumatic drugs.
Thursday, August 23, 2012
New Real World Clinical Data Showed Vimpat® (lacosamide) Effective in Achieving Seizure Control
At final follow-up 31.1% patients reported =50% seizures reduction and 9.8% were seizure free.
Friday, July 06, 2012
UCB to Showcase Immunology Portfolio at EULAR 2012
Data to be presented on certolizumab pegol, epratuzumab and CDP7851/AMG 785.
Thursday, July 05, 2012
UCB and Domainex Collaboration Provides Valuable Information on Cancer Drug Target
New structural information allowed UCB scientists to design a novel class of molecules which inhibit MEK.
Thursday, March 15, 2012
UCB CEO to Chair Innovative Medicines Initiative Board
Roch Doliveux confirms industry’s commitment to unique EU public-private partnership.
Monday, March 12, 2012
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!